Strategy for the decisions that don't have off-the-shelf answers.
WHAT WE DOFour capabilities for the decisions that shape a commercial trajectory.
We work with commercial and launch leaders on the questions that don't fit a standard framework — because the answer depends as much on how the organisation is set up as on the analysis itself.
Commercial Strategy & Launch Readiness Commercial planning that translates into launch execution — positioning, segmentation, access, and the organisational design to deliver on them.
Competitive Intelligence & Scenario Planning Structured scenario work adapted from Shell's methodology, built for pharma brand teams who need to stress-test decisions under uncertainty. Includes wargaming.
Opportunity Assessment & Business Development Clear-eyed valuations and go/no-go analyses for in-licensing, out-licensing, acquisitions, and portfolio decisions.
Organisational Design & Transformation The strategy that comes with an organisational answer. How the commercial, medical, and access functions need to be structured to deliver the strategy.
HOW WE WORKFour principles that shape every engagement.
The difference between strategy that gets filed and strategy that changes what happens on Monday morning is usually in the approach. Ours has four parts.
Both sides of the table. Fifteen years inside Big Pharma commercial and medical functions, plus partner-level consulting engagements across vaccines, specialty, and rare disease. The recommendations come from someone who has had to implement them, and knows what breaks when they hit the organisation.
Scoping in the first conversation. No multi-round sales cycle. The first call is a working session to stress-test the real question and map what evidence would move the decision. You leave the call knowing whether we're a fit.
A disciplined analytical approach. Every recommendation is traceable to a specific dataset, interview, or framework. When leadership asks "why do we believe that," the answer is on the page. No hidden assumptions, no black boxes.
Strategy that comes with an organisational answer. The best commercial plan dies if the team isn't set up to execute it. Every engagement produces both the strategy and the organisational design to deliver on it — the hidden spine that makes Pharmamosaic different.
SELECTED WORK
Recent engagements.
Zoster in-licensing valuation for European negotiations. A mid-sized specialty pharma was evaluating the in-licensing of a herpes zoster vaccine asset from a larger developer. We built the cross-market valuation framework — epidemiology, access dynamics, realistic uptake, pricing corridors — that became the anchor for their negotiation position. The deal closed on terms aligned with our model, not the licensor's opening ask.
Covid-19 commercial go-to-market build-out across 20+ markets. A vaccine developer needed to stand up commercial operations across Europe and APAC in six months, post-approval. We designed and ran the go-to-market architecture — country prioritisation, pricing frameworks, access sequencing, launch teams, governance — delivered on the compressed timeline.